A federal appeals court has suspended an FDA rule that permitted physicians to mail mifepristone directly to patients, a decision that significantly restricts access to the medication used in the majority of U.S. abortions.
Mifepristone is the first drug in a two-medication abortion regimen. The FDA had authorized remote dispensing through the mail in 2023, expanding access beyond traditional in-person clinic visits. The appeals court's freeze on that permission means patients seeking the drug will now face more limited options for obtaining it.
The ruling reflects deepening legal battles over abortion access following the Supreme Court's 2022 decision to overturn Roe v. Wade, which returned regulation of abortion to the states. Multiple lawsuits have challenged the medication's availability and the FDA's authority to permit mail delivery.
Clinics and advocacy groups have argued that mail access is crucial, particularly in states with strict abortion bans where patients must travel long distances to reach providers in neighboring jurisdictions. Opponents contend that in-person evaluations are necessary for patient safety.
The pause remains in effect while litigation continues through the appeals process. Legal experts say the ultimate fate of mail-order mifepristone will likely depend on how courts interpret FDA authority and how individual states choose to regulate the drug within their borders.
Author James Rodriguez: "This is yet another blow to the shrinking number of women who can actually access abortion care in the current legal landscape."
Comments